tradingkey.logo

CEPI & Merck Partner To Develop Updated Version Of Ebola Vaccine

ReutersJan 21, 2026 7:09 PM

-

  • CEPI BACKS UPDATED ZAIRE EBOLAVIRUS VACCINE THAT AIMS TO IMPROVE VACCINE AFFORDABILITY AND ACCESSIBILITY FOR LOW- AND MIDDLE-INCOME COUNTRIES

  • CEPI: BACKED BY UP TO $30 MLN IN CEPI FUNDING, MSD WILL LEVERAGE HILLEMAN LABORATORIES TO DEVELOP EBOLA VACCINE WITH UPDATED MANUFACTURING PROCESS

  • CEPI: WILL ALSO FUND PHASE 3 IMMUNOBRIDGING CLINICAL TRIAL IN COUNTRIES IN AFRICA WHERE CURRENT EBOLA VACCINE IS APPROVED FOR USE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI